These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 32532329)

  • 1. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
    Lupo KB; Matosevic S
    J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
    Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
    Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
    Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
    Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD155, an onco-immunologic molecule in human tumors.
    Gao J; Zheng Q; Xin N; Wang W; Zhao C
    Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
    Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
    Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
    Lupo KB; Yao X; Borde S; Wang J; Torregrosa-Allen S; Elzey BD; Utturkar S; Lanman NA; McIntosh M; Matosevic S
    Nat Commun; 2024 Mar; 15(1):1909. PubMed ID: 38429294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.
    Okumura G; Iguchi-Manaka A; Murata R; Yamashita-Kanemaru Y; Shibuya A; Shibuya K
    J Exp Med; 2020 Mar; 217(4):1. PubMed ID: 32040157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
    Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
    Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT as an emerging immune checkpoint.
    Harjunpää H; Guillerey C
    Clin Exp Immunol; 2020 May; 200(2):108-119. PubMed ID: 31828774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of inhibitory receptor TIGIT to NK cell education.
    He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
    J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
    Mu Y; Guan X
    Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis.
    Bi J; Zhang Q; Liang D; Xiong L; Wei H; Sun R; Tian Z
    Hepatology; 2014 May; 59(5):1715-25. PubMed ID: 24319005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CD226, TIGIT and CD96 regulate NK cell function and participate in anti-tumor immunity].
    Zhang H; Liu R; Zhang Y; Liu X; Chen L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Sep; 39(9):852-856. PubMed ID: 37732582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155).
    Fuchs A; Cella M; Giurisato E; Shaw AS; Colonna M
    J Immunol; 2004 Apr; 172(7):3994-8. PubMed ID: 15034010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.
    Cooksey LC; Friesen DC; Mangan ED; Mathew PA
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
    Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
    Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.